FDX1 and gastric cancer: Emerging research proved METTL16-mediated m6A modification on FDX1 mRNA was critical for cuproptosis in gastric cancer (GC), and METTL16 lactylation significantly promoted the therapeutic efficacy of the copper ionophore-elesclomol [104].